Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript March 17, 2025
Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.11 EPS, expectations were $-0.09.
Operator: Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2024 Teleconference Call. Please be advised that today’s conference is being recorded. I would now like to turn the conference over to your speaker today. Please go ahead.
Louise Wilkie: Thank you....
